Email

maheshwari.ramineni2@bcm.edu

Positions

AssociateProfessor

Pathology
Baylor College of Medicine
Houston

Director of Thoracic Pathology

Baylor College of Medicine

Member

Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine

Addresses

6720 Bertner Avenue (Hospital)

Suite: Y144H
Houston, TX 77030
United States

BCM-Cullen Building (Office)

Room: BCMC-286A
Houston, TX 77030
United States

Education

MBBS from Kempegowda Institute of Medical Sciences

Bangalore

Residency at Henry Ford Health System

Detroit

Fellowship at University of Texas M.D.Anderson Cancer Center

Houston

Certifications

American Board of Anatomic and Clinical Pathology

Honors & Awards

O'Neal Spjut Leadership Award

Baylor St. Lukes Medical Center

Above and Beyond Award- Thoracic Surgery

Baylor St. Lukes Medical Center

Chief Resident

Henry Ford Hospital

Professional Statement

Dr. Maheshwari Ramineni is an Associate professor of Pathology. She serves as director of Thoracic Pathology at Baylor St. Lukes Medical Center. She is a board-certified Anatomic and Clinical Pathologist with expertise in Thoracic Pathology, Cancer Biomarkers and Oncologic General Surgical Pathology. Her primary areas of clinical and research interest include thoracic malignancies, lung transplantation, interstitial lung diseases (ILD). Her other professional interests include medical education, immunohistochemistry and quality improvement.

Dr. Ramineni serves as a co-investigator in several clinical trials including ‘ LEADER: Neoadjuvant Screening Trial; LCMC4 Evaluation of Actionable Drivers in Early-Stage Lung Cancer. To determine the proportion of patients with stage IA2-III lung cancers who possess actionable oncogenic drivers”, and ‘NEMO: Combination of Induction Durvalumab and Tremelimumab alone versus Durvalumab and Tremelimumab with chemotherapy for Potentially Resectable Pleural Mesothelioma.’

Dr. Ramineni is also a co-investigator on multiple NIH R01 grants including, ‘Validation and translation of Masspec Pen technology for intraoperative evaluation of non-small cell lung cancer ‘, Targeting the Mitochondria to Overcome Resistance to Immune Checkpoint Inhibition in Malignant Pleural Mesothelioma,’ and ‘Novel strategies to improve mesothelioma therapy’.

Prior to her faculty appointment at BCM, Dr. Ramineni trained extensively in the diagnosis of various oncologic malignancies under world-renowned mentors during her fellowship at M.D. Anderson Cancer Center, Houston. She also did combined anatomic and clinical pathology residency at the Henry Ford Hospital and received her Medical Doctorate from Kempegowda Institute of Medical Sciences.

Websites

Selected Publications

• Lee, H. S., Jang, H. J., Ramineni, M., Wang, D. Y., Ramos, D., Choi, J. M., ... & Burt, B. M. (2023) "A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma." ; Pubmed PMID: 36469573
• Jang, H. J., Lee, H. S., Yu, W., Ramineni, M., Truong, C. Y., Ramos, D., ... & Burt, B. M. (2022) "Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment." ; Pubmed PMID: 35709756
• Symmans, W. F., Wei, C., Gould, R., Yu, X., Zhang, Y., Liu, M., ... & Hortobagyi, G. N.(2017) "Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype." ; Pubmed PMID: 28135148
• Tang, M., Abbas, H. A., Negrao, M. V., Ramineni, M., Hu, X., Hubert, S. M., ... & Zhang, J. (2021) "The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics." ; Pubmed PMID: 34873156